Evidence mapPaperPMID 40832121Full record

ArticleClinical kidney journal2025

New biomarkers of inflammation associated with haemodialysis.

Fátima Guerrero, Andrés Carmona, Maria Jose Jiménez, Francisco Ariza, Teresa Obrero, Isabel Berdud, Carolina Carrillo-Carrión, Mariano Rodríguez, Sagrario Soriano, Juan R Muñoz-Castañeda and 1 more

Abstract read
In one paragraph

Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Fátima GuerreroMaimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Córdoba, Reina Sofía University Hospital, Córdoba, Spain.ORCID https://orcid.org/0000-0003-1306-0574
Andrés CarmonaMaimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Córdoba, Reina Sofía University Hospital, Córdoba, Spain.
Maria Jose JiménezMaimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Córdoba, Reina Sofía University Hospital, Córdoba, Spain.
Francisco ArizaMaimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Córdoba, Reina Sofía University Hospital, Córdoba, Spain.
Teresa ObreroMaimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Córdoba, Reina Sofía University Hospital, Córdoba, Spain.
Isabel BerdudDialysis Satellite Unit, Fresenius Medical Care Services Andalucía, Córdoba, Spain.
Carolina Carrillo-CarriónInstitute for Chemical Research (IIQ), CSIC-University of Seville, Seville, Spain.
Mariano RodríguezMaimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Córdoba, Reina Sofía University Hospital, Córdoba, Spain.
Sagrario SorianoMaimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Córdoba, Reina Sofía University Hospital, Córdoba, Spain.
Juan R Muñoz-CastañedaMaimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Córdoba, Reina Sofía University Hospital, Córdoba, Spain.
Alejandro Martín-MaloMaimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Córdoba, Reina Sofía University Hospital, Córdoba, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The first year of haemodialysis (HD) carries the highest risk of mortality, which to a large extent is attributed to the aggravation of inflammation. However, traditional markers such as C-reactive protein and interleukin-6 show only minor changes during the first year, suggesting that there are other factors involved. The present study evaluates the effect of HD on microinflammation and oxidative stress of uremic patients. Methods: We conducted a prospective observational longitudinal study including 30 incident HD patients. Blood samples were collected at baseline and 6 and 12 months. Pro-inflammatory monocytes were quantified using flow cytometry. Proteomic analysis (Olink) was performed on serum. Concentrations of indoxyl sulphate (IS), growth differentiation factor 15 (GDF-15), oxidative status and circulating microRNA (miRNA) expression were also determined. Results: A new population of activated monocytes was identified that progressively increased at 1 year of HD. In addition, an increase in the serum concentration of up to 29 inflammation-related proteins was detected, including interleukins, chemokines, tumour necrosis factor family molecules, cell activation molecules and apoptosis-related proteins. Conversely, leukaemia inhibitory factor receptor was downregulated. The concentration of IS was positively correlated with GDF-15 levels. Furthermore, patients exhibited decreased expression of miRNA-126-3p, -130a-3p, -146a-5p, 223-3p, -let7a-5p and -let7b-5p. Conclusion: This study highlights the impact of HD on inflammation and oxidative stress, manifested by an increase in activated monocytes and inflammatory markers. The observed subclinical inflammation associated to HD treatment may help in understanding the mechanisms of cardiovascular damage in patients on HD.

Indexed as

cardiovascular diseasehaemodialysisinflammationmonocytesuraemic toxins

Identifiers

PMID40832121
PMCPMC12358798

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.